Eli Lilly and Company (LLY) announced positive Phase 3 results for its eczema drug lebrikizumab in pediatric patients, showing sustained skin clearance for up to four years1. The breakthrough marks the first selective IL-13 inhibitor to deliver positive outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis.
Key Takeaways
- EBGLYSS achieved 63% skin improvement, 44% clear skin at Week 16
- First IL-13 inhibitor approved for pediatric moderate-to-severe atopic dermatitis
- Durable itch relief lasting up to four years in clinical studies
Market reaction & context
The positive pediatric data strengthens Lilly’s position in the competitive atopic dermatitis market, where it competes with established treatments like Dupixent from Sanofi and Regeneron. Lebrikizumab, marketed as EBGLYSS, received FDA approval in 2024 for adults and children 12 years and older, making this pediatric expansion crucial for market penetration1.
The drug demonstrated strong efficacy in the ADorable-1 trial, with 63% of patients achieving meaningful skin improvement (EASI-75) and 44% achieving clear or almost clear skin at Week 16. Additionally, 39% of patients reached near-complete skin clearance (EASI-90), while 35% experienced significant itch relief1.
Detailed analysis
EBGLYSS works by selectively targeting interleukin-13 (IL-13), a primary cytokine driving type-2 inflammatory cycles in atopic dermatitis. This mechanism leads to skin barrier dysfunction, persistent itch, skin thickening, and increased infection susceptibility1.
The safety profile remained consistent with previous adult and adolescent studies, with no new safety signals observed. Most common adverse events included upper respiratory tract infections and nasopharyngitis, with notably no injection site pain reported during the trial1.
Outlook & management quote
“Children with moderate-to-severe atopic dermatitis often endure relentless skin flares, itch and discomfort that can disrupt play, school and daily life for patients and caregivers,” said Adrienne Brown, executive vice president and president, Lilly Immunology1. “EBGLYSS has already changed what’s possible for adults and adolescents, delivering durable results that help patients flare less with the option of monthly maintenance dosing.”
Lilly plans to submit these pediatric data to US and global regulators for potential label expansion. The company continues investing in next-generation immunology innovation, including novel oral IL-17 inhibitors and targeted small molecule therapies1.
Long-term efficacy data
Earlier studies demonstrated EBGLYSS’s sustained benefits over two years, with nearly 80% of patients maintaining clear or almost clear skin with monthly maintenance dosing3. The drug’s durability represents a significant advantage in treating this chronic condition that affects 9.6 million children in the US1.
Research shows patients who didn’t initially meet protocol-defined response criteria at 16 weeks still benefited from continued treatment, with 75.5% achieving EASI-75 and 36.1% reaching clear or almost clear skin by Week 524.
Conclusion
The positive pediatric data positions EBGLYSS as a potential first-line biologic treatment for younger atopic dermatitis patients, addressing a significant unmet medical need. With its selective IL-13 inhibition and monthly maintenance dosing option, the drug offers a differentiated profile in the competitive dermatology market.
Not investment advice. For informational purposes only.
References
1Eli Lilly and Company (March 16, 2026). “Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis”. PR Newswire. Retrieved March 27, 2026.
2James Waldron (October 20, 2023). “After FDA knockback, Lilly posts 2-year data showing benefit of eczema treatment lebrikizumab”. Fierce Biotech. Retrieved March 27, 2026.
3“Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly’s lebrikizumab monthly maintenance dosing at two years” (October 20, 2023). Eli Lilly and Company. Retrieved March 27, 2026.
4“The efficacy of longer-term lebrikizumab treatment in patients with moderate-to-severe atopic dermatitis who did not meet protocol-defined response criteria at week 16 in 2 randomized controlled clinical trials” (December 27, 2024). Journal of the American Academy of Dermatology. Retrieved March 27, 2026.
5Erin Hunter (May 4, 2023). “Patients With Atopic Dermatitis on Lebrikizumab Showed Long-Term Clearer Skin”. Pharmacy Times. Retrieved March 27, 2026.